Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 1, 2019

Study Completion Date

June 1, 2019

Conditions

Lip and Oral Cavity Squamous Cell CarcinomaOral Cavity Verrucous CarcinomaPrecancerous Condition

Interventions

DRUG

vandetanib

Given PO

OTHER

placebo

Given PO

OTHER

immunohistochemistry staining method

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

biopsy

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

University of Chicago, Chicago

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT01414426 - Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions | Biotech Hunter | Biotech Hunter